Back to Report Store Home

Global Rheumatic Disorders Drugs Market to 2024 – Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

  • Published: Jan-2019
  • Report Code: GBIHC489MR
  • Report Format: pdf

Description

List of Tables

Table 1: Rheumatic Disorders Drugs Market, Global, Etiology of RA, OA, Osteoporosis, SLE and PsA, 2018

Table 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology of Key Rheumatic Disorders Indications, 2018

Table 3: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within RA, 2018

Table 4: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for RA, 2018

Table 5: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within OA, 2018

Table 6: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for OA, 2018

Table 7: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within Osteoporosis, 2018

Table 8: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for Osteoporosis, 2018

Table 9: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within SLE, 2018

Table 10: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for SLE, 2018

Table 11: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within PsA, 2018

Table 12: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for PsA, 2018

Table 13:Rheumatic Disorders Drugs Market, Global, Key Marketed Products Overview, 2018

Table 14: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Humira, 2018

Table 15: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Enbrel, 2018

Table 16: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Simponi, 2018

Table 17: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Remicade, 2018

Table 18: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Rituxan, 2018

Table 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Stelara, 2018

Table 20: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Cosentyx, 2018

Table 21: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Prolia, 2018

Table 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Orencia, 2018

Table 23: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Actemra, 2018

Table 24: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Benlysta, 2018

Table 25: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Forteo, 2018

Table 26: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017–2024

Table 27: Rheumatic Disorders Drugs Market, Global, Use of Generics Across Key Indications, 2018

Table 28: Rheumatic Disorders Drugs Market, Global, Forecast Revenue by Company (%), 2017–2024

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards